Skip to main content
SpringerLink
Log in

Arginine methylation of ALKBH5 by PRMT6 promotes breast tumorigenesis via LDHA-mediated glycolysis

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

ALKBH5 is a master regulator of N6-methyladenosine (m6A) modification, which plays a crucial role in many biological processes. Here, we show that ALKBH5 is required for breast tumor growth. Interestingly, PRMT6 directly methylates ALKBH5 at R283, which subsequently promotes breast tumor growth. Furthermore, arginine methylation of ALKBH5 by PRMT6 increases LDHA RNA stability via m6A demethylation, leading to increased aerobic glycolysis. Moreover, PRMT6-mediated ALKBH5 arginine methylation is confirmed in PRMT6-knockout mice. Collectively, these findings identify a PRMT6-ALKBH5-LDHA signaling axis as a novel target for the treatment of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wiener D, Schwartz S. The epitranscriptome beyond m6A. Nat Rev Genet 2021; 22(2): 119–131

    Article  CAS  PubMed  Google Scholar 

  2. Oerum S, Meynier V, Catala M, Tisne C. A comprehensive review of m6A/m6Am RNA methyltransferase structures. Nucleic Acids Res 2021; 49(13): 7239–7255

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Huang H, Weng H, Chen J. m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell 2020; 37(3): 270–288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Qu J, Yan H, Hou Y, Cao W, Liu Y, Zhang E, He J, Cai Z. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential. J Hematol Oncol 2022; 15(1): 8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wu L, Wu D, Ning J, Liu W, Zhang D. Changes of N6-methyladenosine modulators promote breast cancer progression. BMC Cancer 2019; 19(1): 326

    Article  PubMed  PubMed Central  Google Scholar 

  6. Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, He X, Semenza GL. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc Natl Acad Sci USA 2016; 113(14): E2047–E2056

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gupta S, Kadumuri RV, Singh AK, Chavali S, Dhayalan A. Structure, activity and function of the protein arginine methyltransferase 6. Life (Basel) 2021; 11(9): 951

    ADS  CAS  PubMed  Google Scholar 

  8. Blanc RS, Richard S. Arginine methylation: the coming of age. Mol Cell 2017; 65(1): 8–24

    Article  CAS  PubMed  Google Scholar 

  9. Chen Z, Gan J, Wei Z, Zhang M, Du Y, Xu C, Zhao H. The emerging role of PRMT6 in cancer. Front Oncol 2022; 12: 841381

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Han X, Ren C, Lu C, Qiao P, Yang T, Yu Z. Deubiquitination of MYC by OTUB1 contributes to HK2 mediated glycolysis and breast tumorigenesis. Cell Death Differ 2022; 29(9): 1864–1873

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lu C, Ren C, Yang T, Sun Y, Qiao P, Han X, Yu Z. Fructose-1, 6-bisphosphatase 1 interacts with NF-κB p65 to regulate breast tumorigenesis via PIM2 induced phosphorylation. Theranostics 2020; 10(19): 8606–8618

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lu C, Qiao P, Sun Y, Ren C, Yu Z. Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer. Clin Transl Med 2021; 11(4): e400

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ren C, Han X, Lu C, Yang T, Qiao P, Sun Y, Yu Z. Ubiquitination of NF-κB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance. Cell Death Differ 2022; 29(2): 381–392

    Article  CAS  PubMed  Google Scholar 

  14. Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, Liu Y, Zhang X, Zhang W, Ye L. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett 2018; 415: 11–19

    Article  CAS  PubMed  Google Scholar 

  15. Han X, Ren C, Yang T, Qiao P, Wang L, Jiang A, Meng Y, Liu Z, Du Y, Yu Z. Negative regulation of AMPKα1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer. Oncogene 2019; 38(38): 6537–6549

    Article  CAS  PubMed  Google Scholar 

  16. Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med 2018; 7(12): 6124–6136

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sendinc E, Shi Y. RNA m6A methylation across the transcriptome. Mol Cell 2023; 83(3): 428–441

    Article  CAS  PubMed  Google Scholar 

  18. Liu Z, Chen Y, Wang L, Ji S. ALKBH5 promotes the proliferation of glioma cells via enhancing the mRNA stability of G6PD. Neurochem Res 2021; 46(11): 3003–3011

    Article  CAS  PubMed  Google Scholar 

  19. Zhu Z, Qian Q, Zhao X, Ma L, Chen P. N6-methyladenosine ALKBH5 promotes non-small cell lung cancer progress by regulating TIMP3 stability. Gene 2020; 731: 144348

    Article  CAS  PubMed  Google Scholar 

  20. Zhu H, Gan X, Jiang X, Diao S, Wu H, Hu J. ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. J Exp Clin Cancer Res 2019; 38(1): 163

    Article  PubMed  PubMed Central  Google Scholar 

  21. Guo T, Liu DF, Peng SH, Xu AM. ALKBH5 promotes colon cancer progression by decreasing methylation of the lncRNA NEAT1. Am J Transl Res 2020; 12(8): 4542–4549

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Zhang J, Guo S, Piao HY, Wang Y, Wu Y, Meng XY, Yang D, Zheng ZC, Zhao Y. ALKBH5 promotes invasion and metastasis of gastric cancer by decreasing methylation of the lncRNA NEAT1. J Physiol Biochem 2019; 75(3): 379–389

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Jiang N, Li QL, Pan W, Li J, Zhang MF, Cao T, Su SG, Shen H. PRMT6 promotes endometrial cancer via AKT/mTOR signaling and indicates poor prognosis. Int J Biochem Cell Biol 2020; 120: 105681

    Article  CAS  PubMed  Google Scholar 

  24. Pan R, Yu H, Dai J, Zhou C, Ying X, Zhong J, Zhao J, Zhang Y, Wu B, Mao Y, Wu D, Ying J, Duan S. Significant association of PRMT6 hypomethylation with colorectal cancer. J Clin Lab Anal 2018; 32(9): e22590

    Article  PubMed  PubMed Central  Google Scholar 

  25. Okuno K, Akiyama Y, Shimada S, Nakagawa M, Tanioka T, Inokuchi M, Yamaoka S, Kojima K, Tanaka S. Asymmetric dimethylation at histone H3 arginine 2 by PRMT6 in gastric cancer progression. Carcinogenesis 2019; 40(1): 15–26

    Article  CAS  PubMed  Google Scholar 

  26. Almeida-Rios D, Graca I, Vieira FQ, Ramalho-Carvalho J, Pereira-Silva E, Martins AT, Oliveira J, Goncalves CS, Costa BM, Henrique R, Jerónimo C. Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer. Oncotarget 2016; 7(33): 53018–53028

    Article  PubMed  PubMed Central  Google Scholar 

  27. Dowhan DH, Harrison MJ, Eriksson NA, Bailey P, Pearen MA, Fuller PJ, Funder JW, Simpson ER, Leedman PJ, Tilley WD, Brown MA, Clarke CL, Muscat GEO. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocr Relat Cancer 2012; 19(4): 509–526

    Article  CAS  PubMed  Google Scholar 

  28. Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, Nakamura Y, Hamamoto R. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 2011; 128(3): 562–573

    Article  CAS  PubMed  Google Scholar 

  29. Avasarala S, Wu PY, Khan SQ, Yanlin S, Van Scoyk M, Bao J, Di Lorenzo A, David O, Bedford MT, Gupta V, Winn RA, Bikkavilli RK. PRMT6 promotes lung tumor progression via the alternate activation of tumor-associated macrophages. Mol Cancer Res 2020; 18(1): 166–178

    Article  CAS  PubMed  Google Scholar 

  30. Hyllus D, Stein C, Schnabel K, Schiltz E, Imhof A, Dou Y, Hsieh J, Bauer UM. PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev 2007; 21(24): 3369–3380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Guccione E, Bassi C, Casadio F, Martinato F, Cesaroni M, Schuchlautz H, Luscher B, Amati B. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature 2007; 449(7164): 933–937

    Article  ADS  CAS  PubMed  Google Scholar 

  32. Kim S, Kim NH, Park JE, Hwang JW, Myung N, Hwang KT, Kim YA, Jang CY, Kim YK. PRMT6-mediated H3R2me2a guides Aurora B to chromosome arms for proper chromosome segregation. Nat Commun 2020; 11(1): 612

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  33. Liu L, Zhang X, Ding H, Liu X, Cao D, Liu Y, Liu J, Lin C, Zhang N, Wang G, Hou J, Huang B, Zhang Y, Lu J. Arginine and lysine methylation of MRPS23 promotes breast cancer metastasis through regulating OXPHOS. Oncogene 2021; 40(20): 3548–3563

    Article  CAS  PubMed  Google Scholar 

  34. Yan WW, Liang YL, Zhang QX, Wang D, Lei MZ, Qu J, He XH, Lei QY, Wang YP. Arginine methylation of SIRT7 couples glucose sensing with mitochondria biogenesis. EMBO Rep 2018; 19(12): e46377

    Article  PubMed  PubMed Central  Google Scholar 

  35. Wong TL, Ng KY, Tan KV, Chan LH, Zhou L, Che N, Hoo RLC, Lee TK, Richard S, Lo CM, Man K, Khong PL, Ma S. CRAF methylation by PRMT6 regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation. Hepatology 2020; 71(4): 1279–1296

    Article  CAS  PubMed  Google Scholar 

  36. Wang H, Xu B, Shi J. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2. Gene 2020; 722: 144076

    Article  CAS  PubMed  Google Scholar 

  37. Bhattarai PY, Kim G, Lim SC, Mariappan R, Ohn T, Choi HS. METTL3 stabilization by PIN1 promotes breast tumorigenesis via enhanced m6A-dependent translation. Oncogene 2023; 42(13): 1010–1023

    Article  CAS  PubMed  Google Scholar 

  38. Ouyang D, Hong T, Fu M, Li Y, Zeng L, Chen Q, He H, Wen Y, Cheng Y, Zhou M, Zou Q, Yi W. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer. Breast Cancer Res 2023; 25(1): 19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E, Semenza GL. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Oncotarget 2016; 7(40): 64527–64542

    Article  PubMed  PubMed Central  Google Scholar 

  40. Liu H, Lyu H, Jiang G, Chen D, Ruan S, Liu S, Zhou L, Yang M, Zeng S, He Z, Wang H, Li H, Zheng G, Liu B. ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer. Cancer Res 2022; 82(21): 3974–3986

    Article  CAS  PubMed  Google Scholar 

  41. Gong PJ, Shao YC, Yang Y, Song WJ, He X, Zeng YF, Huang SR, Wei L, Zhang JW. Analysis of N6-Methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer. Front Oncol 2020; 10: 578963

    Article  PubMed  PubMed Central  Google Scholar 

  42. Dong XF, Wang Y, Huang BF, Hu GN, Shao JK, Wang Q, Tang CH, Wang CQ. Downregulated METTL14 expression correlates with breast cancer tumor grade and molecular classification. BioMed Res Int 2020; 2020: 8823270

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The study was supported by research grants from National Natural Science Foundation of China (Nos. 81972489 and 82003201), National Natural Science Foundation of Shandong Province (Nos. ZR2020YQ58 and ZR2020QH255), Shandong Province College Science and Technology Plan Project (No. J17KA254), Projects of medical and health technology development program in Shandong Province (No. 2018WS057).

Author information

Author notes

  1. These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Reproductive Medicine, Affiliated Hospital of Weifang Medical University, Weifang, 261053, China

    Xue Han, Chune Ren, Aifang Jiang, Jiayi Lu, Xi Ling, Chao Lu & Zhenhai Yu

  2. Department of Pathology, Affiliated Hospital of Weifang Medical University, Weifang, 261053, China

    Yonghong Sun

Authors
  1. Xue Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chune Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aifang Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yonghong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiayi Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xi Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhenhai Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhenhai Yu.

Ethics declarations

Conflict of interest Xue Han, Chune Ren, Aifang Jiang, Yonghong Sun, Jiayi Lu, Xi Ling, Chao Lu, and Zhenhai Yu declare that they have no conflict of interest.

All procedures performed in studies involving human samples were approved by the Ethics Committee of Weifang Medical University, and in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Patients gave written informed consent for participation, and the rest of the gene expression patient data sets are already published and publicly available. Animal experiments were performed according to the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals, and were approved by the ethics committee of Weifang Medical University.

Supplementary Data

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Han, X., Ren, C., Jiang, A. et al. Arginine methylation of ALKBH5 by PRMT6 promotes breast tumorigenesis via LDHA-mediated glycolysis. Front. Med. (2024). https://doi.org/10.1007/s11684-023-1028-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11684-023-1028-4

Keywords

Search

Navigation